The UK Department of Health and Social Care (DHSC) proposes £39 million ($48.5 million) of funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).
Of this new funding package, up to £24 million over four years has been awarded to bolster the UK’s partnership with CARB-X – a global AMR research initiative – to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world.
The UK has already given £20 million of its ringfenced Official Development Assistance (ODA) budget to the initiative which, together with other funders, has resulted in CARB-X in turn investing nearly £40 million into the UK’s world-leading science and innovation industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze